# 第七章　參考文獻


1. Kaufmann AH Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. *Cancer Res* 1989; 49: 5870-5878.
2. Walker PR, et al. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. *Cancer Res* 1991; 51: 1078-1085.
3. Ling YH, et al. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. *Cancer Res* 1993; 53: 1845-1852.
4. Stevnsner T, et al. Studies on the role of topoisomerase in general, gene- and strand-specific DNA repair. *Carcinogenesis* 1993; 14: 1841-1850.
5. Kerr JFR, et al. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* 1972; 26: 239-257.
6. Hollman PCH, et al. Absorption, metabolism and health effects of dietary flavonoids in man. *Biomed Pharmacother* 1996; 51: 305-310.
7. Kobashi K, et al. Metabolism of sennosides by human intestinal bacteria. *Planta Med* 1980; 40: 225-36
8. Westendorf J. Genotoxicity of naturally occurring hydroxyl-anthraquinone. *Mutat Res* 1990; 240: 1-12.
9. Driscoll JS, et al. Structure-antitumor activity relationships among quinone derivatives. *Cancer Chemother Rep* 1974; 2(4): 1-362.
10. Grimaudo S, et al. Effects of highly purified anthraquinoid compounds from *Aloe vera* on sensitive and multidrug resistant leukemia cells. *Oncol Rep* 1997; 4: 341-343.
11. Pecere T, et al. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. *Cancer Res* 2000; 60: 2800-2804.
12. Lee HZ, et al. Effects and mechanisms of aloe-emodin on cell death in human lung squamous cell carcinoma. *Eur J Pharmacol* 2001; 431:

287-295.

13. Kuo PL, et al. The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines. *Life Sci* 2002; 71: 1879-1892.
14. Carr, Jacqueline H.; Bernadette, F. Rodak. Clinical hematology atlas. Philadelphia : Saunders, 1999.
15. Henderson, L. M.; Chappel, J. B. NADPH oxidase of neutrophils. *Biochim. Biophys. Acta.* 1996; 1273(2): 87-107.
16. Alberts, B.; Bray, D.; Lewis, J.; Raff, M.; Roberts, K.; Watson, J. D. *Mol. Biol. Cell.* 1983; pp.918-924.
17. Edwards, S. W. in Biochemistry and physiology of the neutrophil, Cambridge University Press, London.1994.
18. Kakizuka, A.; Miller, W. H; Jr. Umesono, K. ; Warrell, R. P; Jr. Frankel, S. R.;Murty, V. V.; Dmitrovsky, E.; Evans, R. M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. *Cell* 1991; 66(4): 663-674.
19. Landis, S. H.; Murray, T.; Bolden, S.; Wingo, P. A. Cancer statistics, *Ca: a Cancer Journal for Clinicians.* 1998; 48(1): 6-29.
20. Stone, R. M.; Mayer, R. J. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. *Hematol. Oncol. Clin. N. Am.* 1993; 7(1): 47-64.
21. Hoelzer, D. F. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. *Hematol. Oncol. Clin. N. Am.* 1993; 7(1): 139-160.
22. Kantarjian, H. M.; Smith, T. L.; O'Brien, S.; Beran, M.; Pierce, S.; Talpaz, M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. *An. Intern. Med.* 1995; 122(4): 254-261.
23. Faguet, G. B. Chronic lymphocytic leukemia: an updated review. *J. Clin. Oncol.* 1994; 12(9): 1974-1990.

24. Reynolds, T. The compounds in Aloe leaf exudates: a review. *Bot. J. Linn. Soc.* 1985; 90: 157–177.
25. Fairbairn, J. W. Natural anthraquinone drugs. *Pharmacology* 1980; 20 (Suppl. 1): 2–122.
26. Yang, F., Zhang, T., Tian, G., Cao, H., Liu, Q., Ito, Y.,. Preparative isolation and purification of hydroxyanthraquinones from *Rheum officinale* Baill by high-speed counter-current chromatography using pH-modulated stepwise elution. *J. Chromatogry* 1999; A 858: 103–107.
27. Krumbiegel G, Schulz HU. Rhein and aloe-emodin kinetics from senna laxatives in man. *Pharmacology* 1993; 47(Suppl 1): 120–4.
28. Agarwal SK, Singh SS, Verma S, Kumar S. Antifungal activity of anthraquinone derivatives from Rheum emodin *Journal of Ethnopharmacology* 2000; 72(1–2): 43–6.
29. Hatano T, Uebayashi H, Ito H, Shiota S, Tsuchiya T, Yoshida T. Phenolic constituents of Cassia seeds and antibacterialeffect of some naphthalenes and anhraquinones on methicillin-resistant Staphylococcus aureus. *Chemical and Pharmaceutical Bulletin* 1999; 47(8): 1121–7.
30. Andersen DO, Weber ND, Wood SG, Hughes BG, Murray BK, North JA. In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives. *Antiviral Research* 1991; 16(2): 185–96.
31. Arosio B, Gagliano N, Fusaro LM, Parmeggiani L, Tagliabue J, Galetti P, De Castri D, Moscheni C, Annoni G. Aloe-Emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride. *Pharmacology and Toxicology* 2000; 87(5):229–33.
32. Manish A. Shah and Gary K. Schwartz Cell Cycle-mediated Drug Resistance: An Emerging Concept in Cancer Therapy *Clinical Cancer Research* 2001; 7: 2168–2181.

33. Smith ML, and Fornace AJ Jr. Mammalian DNA damage-inducible genes associated with growth arrest and apoptosis. *Mutation Research*. 1996; 340(2-3):109-24.
34. Sherr CJ. G1 phase progression: cycling on cue. *Cell.* 1994; 79(4):551-5,
35. Draetta GF. Mammalian G1 cyclins. *Current Opinion in Cell Biology.* 1994; 6(6):842-6.
36. Hunter T, and Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age *Cell.* 1994; 79(4):573-82.
37. King RW, Jackson PK, and Kirschner MW. Mitosis in transition *Cell.* 1994; 79(4):563-71.
38. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, and Slingerland J. G1 control in mammalian cells. *Journal of Cell Science - Supplement.* 1994; 18:69-73.
39. Morgan DO. Principles of CDK regulation. *Nature.* 1995; 374(6518):131-4
40. Sherr CJ, and Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes & Development.* 1995; 9 (10):1149-63.
41. Brooks, R., Fantes, P., Hunt, T., and Wheatley, D. eds. The cell cycle. Cambridge: The Company of Biologists Ltd, 1989
42. Hutchison, C., and Glover, D.M. Cell cycle control. New York: Oxford University Press., 1995
43. Tyson, J.J., Novak, B., Odell, G.M., Chen, K., and Thron, C.D. Chemical kinetic theory: understanding cell-cycle regulation. *TIBS.* 1996; 21: 89-95.
44. McGill, C.J., and Brooks, G. Cell cycle control mechanisms and their role in cardiac growth. *Cardiovasc. Res.* 1995; 30: 557-69.
45. Martinez, A.M., Afshar, M., Martin, F., Cavadore, J.C., Labbé, J.C., and Dorée, M. Dual phosphorylation of the T-loop in cdk7: its role in controlling cyclin H binding and CAK activity. *EMBO J.* 1997; 16: 343-354.

46. Andersen, G., Busso, D., Poterszman, A., Hwang, J.R., Wurtz, J.M., Ripp, R., Thierry, J.C., Egly, J.M., and Moras, D. The structure of cyclin H: common mode of kinase activation and specific features. *EMBO. J.* 1997; 16: 958-967.
47. Li, J.M., and Brooks, G. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system. *Eur. Heart J.* 1999; 20: 406-420.
48. Reed, S.I., Bailly, E., Dulic, V., Hengst, L., Resnitzky, D., and Slingerland, J. G1 control in mammalian cells. *J. Cell Sci. Suppl.* 1994; 18: 69-73.
49. Pines, J. Cyclin-dependent kinase inhibitors: the age of crystals. *Biochem. Biophys. Acta.* 1997; 1332: M39-M42.
50. Brooks, G., Poolman, R.A., and Li, J.M. Arresting developments in the cardiac myocyte cell cycle: Role of cyclin- dependents kinase inhibitors. *Cardiovasc. Res.* 1998; 39: 301-311
51. Kerr, J. F., Wyllie, A. H., and Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics *Br J Cancer*.1972; 26: 239-57.
52. Lockshin, R. A. and Beaulaton, J. Programmed cell death *Life Sci.* 1974; 15: 1549-65.
53. Zakeri, Z. and Lockshin, R. A. Physiological cell death during development and its relationship to aging *Ann N Y Acad Sci.* 1994; 719: 212-29.
54. Ishizaki, Y. Physiological functions of programmed cell death *Seikagaku*. 1998; 70: 365-70.
55. Reed, J. C. Mechanisms of apoptosis avoidance in cancer *Curr Opin Oncol*. 1999; 11: 68-75.
56. Behl, C. Apoptosis and Alzheimer's disease, *J Neural Transm.* 2000; 107: 1325-44.

57. Cotman, C. W., Whittemore, E. R., Watt, J. A., Anderson, A. J., and Loo, D. T. Possible role of apoptosis in Alzheimer's disease, *Ann N Y Acad Sci.* 1994; 747: 36-49.
58. Cotman, C. W. and Anderson, A. J. A potential role for apoptosis in neurodegeneration and Alzheimer's disease, *Mol Neurobiol.* 1995; 10: 19-45.
59. Perry, G., Nunomura, A., Lucassen, P., Lassmann, H., and Smith, M. A. Apoptosis and Alzheimer's disease, *Science.* 1998; 282: 1268-9.
60. Searle, J., Kerr, J. F., and Bishop, C. J. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance, *Pathol Annu.* 1982; 17: 229-59.
61. Matsuda, H., Strebel, F. R., Kaneko, T., Stephens, L. C., Danhauser, L. L., Jenkins, G. N., Toyota, N., and Bull, J. M. Apoptosis and necrosis occurring during different stages of primary and metastatic tumor growth of a rat mammary adenocarcinoma, *Anticancer Res.* 1996; 16: 1117-21.
62. Nicotera, P., Leist, M., and Ferrando-May, E. Apoptosis and necrosis: different execution of the same death, *Biochem Soc Symp.* 1999; 66: 69-73.
63. Zhang, J. H. and Xu, M. DNA fragmentation in apoptosis, *Cell Res.* 2000; 10: 205-11.
64. Kameda, K., Kondo, T., Tanabe, K., Zhao, Q. L., and Seto, H. The role of intracellular $Ca^{2+}$ in apoptosis induced by hyperthermia and its enhancement by verapamil in U937 cells, *Int J Radiat Oncol Biol Phys.* 2001; 49: 1369-79.
65. Saleh, H., Schlatter, E., Lang, D., Pauels, H. G., and Heidenreich, S. Regulation of mesangial cell apoptosis and proliferation by intracellular $Ca^{2+}$ signals, *Kidney Int.* 2000; 58: 1876-84.
66. Miller, D. K. The role of the Caspase family of cysteine proteases in apoptosis, *Semin Immunol.* 1997; 9: 35-49.

67. Kuida, K. [Caspase family proteases and apoptosis], Tanpakushitsu Kakusan Koso. 1997; 42: 1630-6.
68. Shi, Y., Mechanisms of caspase activation and inhibition during apoptosis. *Molecular Cell* 2002; 9, 459-470.
69. Zornig, M., Hueber, A.O., Evan, G., Apoptosis regulators and their role in tumorigensis. *Biochemica et Biophysica Acta* 2001; 1551, F1-F37.
70. Leonhard, M., Gruber, P., Chott, P.A., Mutations in apoptosis genes : a pathogenetic factor for human disease. *Mutation Research* 2001; 488, 211-231.
71. Esser, P., Heimann, K., Abts, H., Fontana, A., and Weller, M. CD95 (Fas/APO-1) antibody-mediated apoptosis of human retinal pigment epithelial cells, *Biochem Biophys Res Commun.* 1995; 213: 1026-34.
72. Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., and Fontana, A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines, *J Clin Invest.* 1994; 94: 954-64.
73. Lundberg, A. S. and Weinberg, R. A. Control of the cell cycle and apoptosis, *Eur J Cancer.* 1999; 35: 1886-94.
74. McDonnell, T. J., Beham, A., Sarkiss, M., Andersen, M. M., and Lo, P. Importance of the Bcl-2 family in cell death regulation, *Experientia.* 1996; 52: 1008-17.
75. Ibrado, A. M., Huang, Y., Fang, G., Liu, L., and Bhalla, K. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL- 60 cells, *Cancer Res.* 1996; 56: 4743-8.
76. Han, Z., Chatterjee, D., Early, J., Pantazis, P., Hendrickson, E. A., and Wyche, J. H. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL, *Cancer Res.* 1996; 56: 1621-8.

77. Reed, J. C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance, *Curr Opin Oncol.* 1995; 7: 541-6.
78. Reed, J. C. Bcl-2 family proteins: regulators of chemoresistance in cancer, *Toxicol Lett.* 1995; 82-83: 155-8.
79. Reed, J. C. Double identity for proteins of the Bcl-2 family, *Nature.* 1997; 387: 773-6.
80. Ryan, K. M. and Birnie, G. D. Myc oncogenes: the enigmatic family, *Biochem J.* 1996; 314: 713-21.
81. Lee, W. M. The myc family of nuclear proto-oncogenes, *Cancer Treat Res.* 1989; 47: 37-71.
82. Alt, F. W., DePinho, R., Zimmerman, K., Legouy, E., Hatton, K., Ferrier, P., Tesfaye, A., Yancopoulos, G., and Nisen, P. The human myc gene family, *Cold Spring Harb Symp Quant Biol.* 1986; 51: 931-41.
83. Gross, N., Balmas, K., Beretta Brognara, C., and Tschopp, J. Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma, *Med Pediatr Oncol.* 2001; 36: 111-4.
84. Hartmann, K., Wagelie-Steffen, A. L., von Stebut, E., and Metcalfe, D. D. Fas (CD95, APO-1) antigen expression and function in murine mast cells, *J Immunol.* 1997; 159: 4006-14.
85. Robertson, M. J., Manley, T. J., Pichert, G., Cameron, C., Cochran, K. J., Levine, H., and Ritz, J. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells, *Leuk Lymphoma.* 1995; 17: 51-61.
86. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorcyzyca, W., Hotz, M. A., Lassota, P., and Traganos, F. Features of apoptotic cells measured by flow cytometry. *Cytometry* 1992; 13: 795-808.
87. Garner, D. L. and Johnson, L. A. Viability assessment of mammalian serm using SYBR-14 and propidium iodide. *Biol. Repord.* 1995; 57: 276-284.

88. E Lee, et al. Induction of apoptosis in HL-60 cells by pungent vanilloids, [6]-gingerol and [6]-paradol. *Cancer Lett* 1998; 134: 163-168.
89. Jaroszeski MJ, et al. Flow cytometry protocols. Humanan Press 1998; pp157-165.
90. Jaroszeski MJ, et al. Flow cytometry protocols. Humanan Press 1998; pp67-75.
91. Donaldson KL, et al. Activation of p34cdc2 coincident with taxol-induced apoptosis. *Cell Growth Diff* 1994; 5: 1041-1050.
92. Olivia Aranha, David P. Wood, Jr., and Fazlul H. Sarkar Ciprofloxacin Mediated Cell Growth Inhibition, S/G2-M Cell Cycle Arrest, and Apoptosis in a Human Transitional Cell Carcinoma of the Bladder Cell Line *Clinical Cancer Research* 2000; 6: 891–900.
93. Ethan A. Kohn, Carolyn J. Yoo, and Alan Eastman The Protein Kinase C Inhibitor Gö6976 Is a Potent Inhibitor of DNA Damage-induced S and G2 Cell Cycle Checkpoints *CANCER RESEARCH* 2003; 63: 31–35.
94. Eun-Yi Moon and Adam Lerner Benzylamide Sulindac Analogues Induce Changes in Cell Shape, Loss of Microtubules and G2-M Arrest in a Chronic Lymphocytic Leukemia (CLL) Cell Line and Apoptosis in Primary CLL Cells *CANCER RESEARCH* 2002; 62: 5711–5719.
95. Yi-He Ling, Leonard Liebes, Jian-Dong Jiang, James F. Holland, Peter J. Elliott, Julian Adams, Franco M. Muggia, and Roman Perez-Soler Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines *Clinical Cancer Research* 2003; 9: 1145–1154.
96. Lijia Yu, Linda Orlandi, Pei Wang, Michael S. Orr, Adrian M. Senderowicz, Edward A. Sausvillei, Rosella Silvestrini, Nobumoto Watanabe, Helen Piwnica-Worms, and Patrick M. O' Connor UCN-01 Abrogates G2 Arrest through a Cdc2-dependent Pathway

That Is Associated with Inactivation of the Wee1Hu Kinase and Activation of the Cdc25C Phosphatase *THE JOURNAL OF BIOLOGICAL CHEMISTRY* 1998; 273: 33455–33464.

97. Niculescu AB 3rd, et al. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transition: pRb is acritical determinant in blocking DNA replication and in preventing endoreduplication. *Mol Cell Biol* 1998; 18: 629-43.
98. Shi L, et al. Premature p34cdc2 activation required for apoptosis. *Science* 1994; 263: 1143-1145.
99. Panaro NJ, et al. Flavone acetic acid induces a G2/M cell cycle arrest in mammary carcinoma cells. *Br J Cancer* 1999; 80: 1905-1911.
100. Yano H, et al. The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. *Cancer Res* 1994; 54: 448-454.
101. Solange D, et al. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000; 10: 369-377.
102. Gross A, et al. Bcl-2 family members and the mitochondria in apoptosis. *Genes Dev* 1999; 13: 1899-1911.
103. Imawati B, et al. Biochemical pathways of caspase activation during apoptosis. *Annu Rev Cell Dev Biol* 1999; 15: 269-290.
104. Vander Heiden, et al. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? *Nat Cell Biol* 1999; 1: E209-E216.
105. Zhang L, et al. Role of Bax in the apoptotic response to anticancer agents. *Science* 2002; 90: 989-992.
106. Galvesen G, et al. Caspase activation: the induced-proximity model. *Proc Natl Acad Sci* 1999; 96: 10964-10967.
107. Barkett M, et al. Phosphorylation of IκBα inhibits its deavage by caspase CPP32 in vitro. *J Biol Chem* 1997; 272: 29419-29422.
108. Reuther JY, et al. Apoptosis promotes a caspase-induced amino-terminal truncation of IkBα, that functions as a stable inhibitor of NF-κB. *J Biol Chem* 1999; 274: 20664-20670.